Literature DB >> 10618286

Reversal of human immunodeficiency virus type 1 protein-induced inhibition of natural killer cell activity by alpha interferon and interleukin-2.

M P Nair1, S A Schwartz.   

Abstract

A recombinant fusion peptide, Env-Gag, derived from the human immunodeficiency virus type 1 (HIV-1) genome corresponding to a defined portion of the envelope (Env) and internal core (Gag) proteins was examined for immunoregulatory effects on the cytotoxic activity of natural killer (NK) cell-enriched, large granular lymphocytes (LGL) from healthy donors. Percoll-separated, NK cell-enriched LGL precultured for 24 h with Env-Gag at 10- and 50-ng/ml concentrations, which significantly stimulated lymphocyte proliferation, caused significant suppression of NK cell activity. Denatured Env-Gag did not cause any effect on the NK cell activity of LGL. Two other control peptides, one derived from the Escherichia coli vector used to clone the HIV Env-Gag fusion peptide and the other derived from a non-HIV-1 viral antigen (rubeola virus), did not produce any observable effect on the NK cell activity of LGL, demonstrating the specificity of the effect produced by Env-Gag. Subsequent treatment of LGL with alpha interferon (IFN-alpha) or interleukin 2 (IL-2) alone partially reversed the Env-Gag-induced suppression of NK cell activity. However, LGL treated with both IFN-alpha and IL-2 completely reversed the suppression of NK cell cytotoxicity by Env-Gag. The combined effect of IFN-alpha and IL-2 in enhancing NK cell activity may provide a novel therapeutic approach to the restoration of depressed NK cell activity observed in HIV-infected patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10618286      PMCID: PMC95831          DOI: 10.1128/CDLI.7.1.101-105.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  43 in total

1.  Cytokine augmentation of human immunodeficiency virus type 1 (HIV-1) gp120-specific cellular cytotoxicity.

Authors:  K C Stine; D Bolognesi; K J Weinhold
Journal:  J Biol Response Mod       Date:  1989-10

2.  Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.

Authors:  F W Ruscetti; J A Mikovits; V S Kalyanaraman; R Overton; H Stevenson; K Stromberg; R B Herberman; W L Farrar; J R Ortaldo
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

3.  Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes.

Authors:  M P Nair; R Pottathil; E P Heimer; S A Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

Review 4.  Pathogenesis of the natural killer cell deficiency in AIDS.

Authors:  M C Sirianni; F Tagliaferri; F Aiuti
Journal:  Immunol Today       Date:  1990-03

5.  Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides.

Authors:  R Cauda; M Tumbarello; L Ortona; P Kanda; R C Kennedy; T C Chanh
Journal:  Cell Immunol       Date:  1988-08       Impact factor: 4.868

6.  Changes in natural immunity during the course of HIV-1 infection.

Authors:  B G Brenner; C Gryllis; M Gornitsky; M A Wainberg
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

7.  Comparison of recombinant human immunodeficiency virus gag precursor and gag/env fusion proteins and a synthetic env peptide as diagnostic reagents.

Authors:  R L Shoeman; D Young; R Pottathil; J Victor; R R Conroy; R M Crowl; T Coleman; E Heimer; C Y Lai; K Ganguly
Journal:  Anal Biochem       Date:  1987-03       Impact factor: 3.365

8.  Interleukin-2 inhibits HIV-1 replication in human macrophages by modulating expression of CD4 and CC-chemokine receptor-5.

Authors:  J Kutza; M P Hayes; K A Clouse
Journal:  AIDS       Date:  1998-05-28       Impact factor: 4.177

Review 9.  Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases.

Authors:  B G Brenner; A Dascal; R G Margolese; M A Wainberg
Journal:  J Leukoc Biol       Date:  1989-07       Impact factor: 4.962

10.  Subregions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals.

Authors:  U Certa; W Bannwarth; D Stüber; R Gentz; M Lanzer; S Le Grice; F Guillot; I Wendler; G Hunsmann; H Bujard
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  2 in total

1.  Hematological manifestations of human immunodeficiency virus infection and the effect of highly active anti-retroviral therapy on cytopenia.

Authors:  Se Youn Choi; Inho Kim; Nam Joong Kim; Seung-Ah Lee; Youn-Ak Choi; Ji-Yeon Bae; Ji Hyun Kwon; Pyoeng Gyun Choe; Wan Beom Park; Sung-Soo Yoon; Seonyang Park; Byoung Kook Kim; Myoung-Don Oh
Journal:  Korean J Hematol       Date:  2011-12-27

2.  The Route of Vaccine Administration Determines Whether Blood Neutrophils Undergo Long-Term Phenotypic Modifications.

Authors:  Yanis Feraoun; Jean-Louis Palgen; Candie Joly; Nicolas Tchitchek; Ernesto Marcos-Lopez; Nathalie Dereuddre-Bosquet; Anne-Sophie Gallouet; Vanessa Contreras; Yves Lévy; Frédéric Martinon; Roger Le Grand; Anne-Sophie Beignon
Journal:  Front Immunol       Date:  2022-01-04       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.